Search research articles
Contact Us
Filters
Showing results (81-90 of 129) with videos related to
Page
of 13
Sort By:
JNCI Cancer Spectrum
|
January 30, 2025
A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancer
Nickolas Stabellini, Omar M Makram, Harikrishnan Hyma Kunhiraman, et al.
JACC. Cardiooncology
|
August 24, 2023
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: <i>JACC: CardioOncology</i> State-of-the-Art Review
Darryl P Leong, Filipe Cirne, Nazanin Aghel, et al.
Breast Cancer Research and Treatment
|
April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial
Christian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
Genome Medicine
|
April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers
Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
JACC. Cardiooncology
|
August 16, 2021
Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology
Daniel J Lenihan, Michael G Fradley, Susan Dent, et al.
Molecular Oncology
|
March 9, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Jessica W Chen, William Jacot, Javier Cortés, et al.
Cancers
|
June 12, 2026
Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies
Kalliopi Keramida, Marianne C Aznar, Jutta Bergler-Klein, et al.
Cancers
|
November 27, 2025
The B-S<sub>2</sub>CALED Score's Utility in Predicting Stroke Risk in Breast Cancer Patients with Atrial Fibrillation
Lakshya Seth, Nickolas Stabellini, Aditya Bhave, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response
Nan Soon Wong, Robert A Buckman, Mark Clemons, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 129) with videos related to
Sort By:
Page
of 13
JNCI Cancer Spectrum
|
January 30, 2025
A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancer
Nickolas Stabellini, Omar M Makram, Harikrishnan Hyma Kunhiraman, et al.
JACC. Cardiooncology
|
August 24, 2023
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: <i>JACC: CardioOncology</i> State-of-the-Art Review
Darryl P Leong, Filipe Cirne, Nazanin Aghel, et al.
Breast Cancer Research and Treatment
|
April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial
Christian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
Genome Medicine
|
April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers
Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
JACC. Cardiooncology
|
August 16, 2021
Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology
Daniel J Lenihan, Michael G Fradley, Susan Dent, et al.
Molecular Oncology
|
March 9, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Jessica W Chen, William Jacot, Javier Cortés, et al.
Cancers
|
June 12, 2026
Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies
Kalliopi Keramida, Marianne C Aznar, Jutta Bergler-Klein, et al.
Cancers
|
November 27, 2025
The B-S<sub>2</sub>CALED Score's Utility in Predicting Stroke Risk in Breast Cancer Patients with Atrial Fibrillation
Lakshya Seth, Nickolas Stabellini, Aditya Bhave, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response
Nan Soon Wong, Robert A Buckman, Mark Clemons, et al.
Page
of 13